Q-omics provides the consensus-scored IFNWP18 profile across patient tissues and cancer cell-line models. IFNWP18 expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, IFNWP18 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, IFNWP18 RNA expression shows 5,582 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight COAD, KIRC, and STAD as cancer lineages where IFNWP18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IFNWP18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IFNWP18 survival associations across molecular data types. IFNWP18 RNA expression shows survival associations in the most cancer types (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IFNWP18 RNA expression–survival associations across cancer types. High IFNWP18 expression shows unfavorable associations in COAD, STAD, LUAD, GBM, PCPG and ESCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify COAD as the clearest survival context for IFNWP18 RNA expression.
This table summarizes IFNWP18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for IFNWP18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IFNWP18 shows lower tumor expression in KIRC, KICH and KIRP. The KIRC box plot shows higher IFNWP18 RNA expression in normal versus tumor tissue (log2 FC = −0.147, t-test p < 0.001).
This table shows molecular features associated with IFNWP18 in patient tissues and cancer cell lines. In patient samples, IFNWP18 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
